Table 1 Patient age, tumor characteristics, hormone receptor status, and systemic treatment in relation to stomatin expression in women with HER2-positive breast cancers (n = 68) and HER2-negative breast cancers (n = 58)
From: Decreased expression of stomatin predicts poor prognosis in HER2-positive breast cancer
Patient Characteristics | HER2-positive | HER2-negative | ||||
|---|---|---|---|---|---|---|
Stomatin (+) (n = 36) | Stomatin (−) (n = 32) | p values | Stomatin (+) (n = 38) | Stomatin (−) (n = 20) | p values | |
Mean age (year) | 53 | 58 | 0.109* | 54 | 52 | 0.659* |
Grade | ||||||
I | 6 | 4 | 0.432† | 3 | 1 | 0.882† |
II | 27 | 22 | 30 | 15 | ||
III | 3 | 6 | 5 | 4 | ||
Stage | ||||||
I | 9 | 5 | 0.420† | 13 | 5 | 0.857† |
II | 13 | 17 | 12 | 8 | ||
III | 13 | 8 | 12 | 7 | ||
IV | 1 | 2 | 1 | 0 | ||
Estrogen receptor | ||||||
Positive | 21 | 17 | 0.807† | 27 | 16 | 0.541† |
Negative | 15 | 15 | 11 | 4 | ||
Progesterone receptor | ||||||
Positive | 20 | 14 | 0.466† | 25 | 16 | 0.366† |
Negative | 16 | 18 | 13 | 4 | ||
Hormonal therapy | ||||||
No | 17 | 13 | 0.631† | 10 | 4 | 0.751† |
Yes | 19 | 19 | 28 | 16 | ||
Surgery | ||||||
Mastectomy | 22 | 18 | 0.711† | 32 | 15 | 0.540† |
Lumpectomy | 14 | 13 | 5 | 5 | ||
No surgery | 0 | 1 | 1 | 0 | ||
Chemotherapy | ||||||
None | 3 | 2 | 0.702† | 10 | 9 | 0.333† |
Adjuvant/Neoadjuvant | ||||||
Anthracycline | 20 | 20 | 23 | 8 | ||
Anthracycline + Taxane | 8 | 7 | 4 | 3 | ||
CMF§ | 3 | 1 | 0 | 0 | ||
Taxane | 1 | 0 | 0 | 0 | ||
Palliative | ||||||
Anthracycline | 1 | 0 | 1 | 0 | ||
Anthracycline + Taxane | 0 | 2 | 0 | 0 | ||
Trastuzumab therapy | ||||||
No | 21 | 17 | 0.175† | N/A | N/A | N/A |
Adjuvant | 12 | 7 | ||||
Palliative | 3 | 8 | ||||